Targeted chemotherapy with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in metastatic breast cancer: which benefit for which patients?

ICE II: An investigational randomized phase II study on epirubicin (E) plus cyclophospamide (C) (or CMF) versus nab-paclitaxel plus capecitabine (PX) as adjuvant chemotherapy for elderly nonfrail patients with an increased risk for relapse of a primary carcinoma of the breast.

(2017) G. Von Minckwitz   JOURNAL OF CLINICAL ONCOLOGY

TBCRC 019: An open-label, randomized, phase II trial of nanoparticle albumin-bound paclitaxel with or without the anti-death receptor 5 (DR5) monoclonal antibody tigatuzumab in patients with metastatic, triple-negative (ER, PR, and HER2-negative) breast cancer.

(2017) A. Forero-Torres et al.   JOURNAL OF CLINICAL ONCOLOGY

Use of Cytotoxic Chemotherapy in Metastatic Breast Cancer: Putting Taxanes in Perspective

(2016) Jasgit C. Sachdev et al.   Clinical Breast Cancer

Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto—GBG 69): a randomised, phase 3 trial

(2016) Michael Untch et al.   LANCET ONCOLOGY

Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer

(2015) Edgardo Rivera et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

HER2-positive metastatic breast cancer: A changing scenario

(2015) G. Mustacchi et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance)

(2015) Hope S. Rugo et al.   JOURNAL OF CLINICAL ONCOLOGY

Prospective study on nanoparticle albumin-bound paclitaxel in advanced breast cancer: clinical results and biological observations in taxane-pretreated patients

(2015) Alessandra Fabi et al.   Drug Design Development and Therapy

Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life

(2015) Raffaella Palumbo et al.   Drug Design Development and Therapy

Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy

(2014) J. L. Lindner et al.   ANNALS OF ONCOLOGY

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†

(2014) F. Cardoso et al.   ANNALS OF ONCOLOGY

Cancer statistics, 2014

(2014) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

nab-Paclitaxel in combination with biologically targeted agents for early and metastatic breast cancer

(2014) Christine Megerdichian et al.   CANCER TREATMENT REVIEWS

nab-Paclitaxel for the Treatment of Aggressive Metastatic Breast Cancer

(2014) Stefan Glück   Clinical Breast Cancer

Nab-paclitaxel: A flattering facelift

(2014) A. Viúdez et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Evaluating the role of nab-paclitaxel (Abraxane) in women with aggressive metastatic breast cancer

(2014) Eva Ciruelos et al.   Expert Review of Anticancer Therapy

Age-Related Changes in Nanoparticle Albumin-Bound Paclitaxel Pharmacokinetics and Pharmacodynamics: Influence of Chronological Versus Functional Age

(2014) A. Hurria et al.   ONCOLOGIST

Triple-negative breast cancer: bridging the gap from cancer genomics to predictive biomarkers

(2014) S. Lindsey Davis et al.   Therapeutic Advances in Medical Oncology

Medical Treatment Of Elderly Patients With Breast Cancer

(2013) Sergio Palmeri et al.   Anti-Cancer Agents in Medicinal Chemistry

nab-Paclitaxel for first-line treatment of patients with metastatic breast cancer and poor prognostic factors: a retrospective analysis

(2013) Joyce O’Shaughnessy et al.   BREAST CANCER RESEARCH AND TREATMENT

Nab-Paclitaxel/Bevacizumab/Carboplatin Chemotherapy in First-Line Triple Negative Metastatic Breast Cancer

(2013) Erika Hamilton et al.   Clinical Breast Cancer

Randomized Phase II Trial of Weekly vs. Every 2 Weeks vs. Every 3 Weeks Nanoparticle Albumin-Bound Paclitaxel With Bevacizumab as First-Line Chemotherapy for Metastatic Breast Cancer

(2013) Andrew D. Seidman et al.   Clinical Breast Cancer

Evaluation of the clinical benefits of nanoparticle albumin-bound paclitaxel in women with metastatic breast cancer in British Columbia

(2013) A.E. Lohmann et al.   Current Oncology

Clinical outcomes of women with metastatic breast cancer treated with nab-paclitaxel: experience from a single academic cancer centre

(2013) S. Dent et al.   Current Oncology

Which patients with metastatic breast cancer benefit from subsequent lines of treatment? An update for clinicians

(2013) Raffaella Palumbo et al.   Therapeutic Advances in Medical Oncology

Docetaxel rechallenge after a first response in non-resistant metastatic breast cancer: significant activity with manageable toxicity

(2012) M. Toulmonde et al.   BREAST CANCER RESEARCH AND TREATMENT

Phase II study evaluating lapatinib in combination with nab-paclitaxel in HER2-overexpressing metastatic breast cancer patients who have received no more than one prior chemotherapeutic regimen

(2012) Denise A. Yardley et al.   BREAST CANCER RESEARCH AND TREATMENT

Phase II Trial of Nab-Paclitaxel Compared With Docetaxel as First-Line Chemotherapy in Patients With Metastatic Breast Cancer: Final Analysis of Overall Survival

(2012) William J. Gradishar et al.   Clinical Breast Cancer

Optimizing taxane use in MBC in the emerging era of targeted chemotherapy

(2012) G. von Minckwitz et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Older patients with breast cancer: is there bias in the treatment they receive?

(2012) Christos Markopoulos et al.   Therapeutic Advances in Medical Oncology

Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: combined analysis of CALGB 9342 and 9840

(2011) S. M. Lichtman et al.   ANNALS OF ONCOLOGY

Late lines of treatment benefit survival in metastatic breast cancer in current practice?

(2011) E. Planchat et al.   BREAST

Weekly nab-paclitaxel is safe and effective in ≥65 years old patients with metastatic breast cancer: A post-hoc analysis

(2011) Matti Aapro et al.   BREAST

A Phase II Study of Weekly Nanoparticle Albumin-Bound Paclitaxel With or Without Trastuzumab in Metastatic Breast Cancer

(2011) Barry Mirtsching et al.   Clinical Breast Cancer

Duration of Chemotherapy for Metastatic Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

(2011) Alessandra Gennari et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment of metastatic breast cancer: second line and beyond

(2010) H. Roche et al.   ANNALS OF ONCOLOGY

Management of triple negative breast cancer

(2010) Catherine Oakman et al.   BREAST

Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer

(2010) Christopher Lobo et al.   BREAST CANCER RESEARCH AND TREATMENT

Phase I Trial of Weekly Tigatuzumab, an Agonistic Humanized Monoclonal Antibody Targeting Death Receptor 5 (DR5)

(2010) Andres Forero-Torres et al.   CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS

Phase II Trial of Weekly Nanoparticle Albumin-Bound Paclitaxel With Carboplatin and Trastuzumab as First-line Therapy for Women With HER2-Overexpressing Metastatic Breast Cancer

(2010) Alison K. Conlin et al.   Clinical Breast Cancer

Nanoparticle albumin-bound (nab™)-paclitaxel: improving efficacy and tolerability by targeted drug delivery in metastatic breast cancer

(2010) Javier Cortes et al.   EJC SUPPLEMENTS

Rechallenging with anthracyclines and taxanes in metastatic breast cancer

(2010) Carlo Palmieri et al.   Nature Reviews Clinical Oncology

Significantly Longer Progression-Free Survival Withnab-Paclitaxel Compared With Docetaxel As First-Line Therapy for Metastatic Breast Cancer

(2009) William J. Gradishar et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognosis of Women With Metastatic Breast Cancer byHER2Status and Trastuzumab Treatment: An Institutional-Based Review

(2009) Shaheenah Dawood et al.   JOURNAL OF CLINICAL ONCOLOGY

Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status

(2008) Neil P. Desai et al.   ANTI-CANCER DRUGS

A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer

(2008) G. Fountzilas et al.   BREAST CANCER RESEARCH AND TREATMENT

Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer

(2008) Edgardo Rivera et al.   CANCER

Metastatic Breast Cancer: The Treatment Challenge

(2008) Stephen E. Jones   Clinical Breast Cancer

Randomized Crossover Pharmacokinetic Study of Solvent-Based Paclitaxel and nab-Paclitaxel

(2008) E. R. Gardner et al.   CLINICAL CANCER RESEARCH

Taxanes in the elderly: Can we gain as much and be less toxic?

(2008) Laura Biganzoli et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Trends in Survival Over the Past Two Decades Among White and Black Patients With Newly Diagnosed Stage IV Breast Cancer

(2008) Shaheenah Dawood et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer and Leukemia Group B Protocol 9840

(2008) Andrew D. Seidman et al.   JOURNAL OF CLINICAL ONCOLOGY

Multiple-Treatments Meta-analysis of Chemotherapy and Targeted Therapies in Advanced Breast Cancer

(2008) Davide Mauri et al.   JNCI-Journal of the National Cancer Institute